# c-Met/HGFR

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

## c-Met/HGFR Inhibitors, Agonists & Activators

### AC-386

Cat. No.: HY-143463

AC-386 is a highly potent **c-Met** inhibitor with $IC_{50}$ value of 7.42 nM. AC-386 has antiproliferative activities against certain cancer cell lines. AC-386 can be used for researching anti-cancer resistance.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

### Altiratinib

**(DCC-2701)**

Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with $IC_{50}$s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.



**Purity:** 98.06%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### AMG-208

Cat. No.: HY-12035

AMG-208 is an orally active **c-Met/RON** dual selective inhibitor with an $IC_{50}$ of 9 nM for c-Met. AMG-208 is a **CYP3A4** inhibitor with an $IC_{50}$ of 32 μM. AMG-208 has anti-cancer activity.



**Purity:** 99.34%
**Clinical Data:** Phase 2
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

### AMG-337

Cat. No.: HY-18696

AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.



**Purity:** 99.36%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

### AMG-458

Cat. No.: HY-14723

AMG-458 is a potent, selective and orally bioavailable **c-Met** inhibitor, with $K_i$ values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### Amuvatinib

**(MP470; HPK 56)**

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



**Purity:** 98.07%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Amuvatinib hydrochloride

**(MP470 hydrochloride; HPK 56 hydrochloride)**

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



**Purity:** >98%
**Clinical Data:** Phase 2
**Size:** 1 mg, 5 mg

### Antitumor agent-45

Cat. No.: HY-144394

Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

### BAY-474

Cat. No.: HY-133083

BAY-474 is a tyrosine-protein kinase **c-Met** inhibitor. BAY-474 acts as an epigenetics probe.



**Purity:** 99.86%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### BMS 777607

**(BMS 817378)**

Cat. No.: HY-12076

BMS 777607 (BMS 817378) is a **Met-related** inhibitor for **c-Met**, **Axl**, **Ron** and **Tyro3** with $IC_{50}$s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity...



**Purity:** 99.04%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg


Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

## BMS-794833

Cat. No.: HY-10497

BMS-794833 is a **VEGFR2** and **Met** inhibitor extracted from patent WO2009094417, compound example 1; has $IC_{50}$s of 15 and 1.7 nM, respectively.



**Purity:** 99.78%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Bozitinib

**(PLB-1001; CBT-101; Vebreltinib)**

Cat. No.: HY-125017

Bozitinib (PLB-1001) is a highly selective **c-MET** kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.



**Purity:** 99.66%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## BPI-9016M

Cat. No.: HY-114356

BPI-9016M is a potent, orally active, and selective dual **c-Met** and **AXL** tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma.



**Purity:** >98%
**Clinical Data:** Phase 1
**Size:** 1 mg, 5 mg

## c-Kit-IN-1

Cat. No.: HY-15240

c-Kit-IN-1 is a potent inhibitor of **c-Kit** and **c-Met** with $IC_{50}$s of <200 nM.



**Purity:** 98.72%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## c-Met inhibitor 1

Cat. No.: HY-15735

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.



**Purity:** 98.01%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## c-Met-IN-1

Cat. No.: HY-101031

c-met-IN-1 (compound 16) is a potent and selective **c-Met** inhibitor, with $IC_{50}$ of 1.1 nM, with antitumor activity.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## c-Met-IN-2

Cat. No.: HY-101773

c-Met-IN-2 is a potent, selective and orally available **c-Met** inhibitor, with an $IC_{50}$ of 0.6 nM, with antitumor activity.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## c-Met-IN-9

Cat. No.: HY-115937

c-Met-IN-9, a 4-phenoxypyridine derivative, is a **c-Met kinas** inhibitor with an $IC_{50}$ of 12 nM. c-Met-IN-9 induces cells **apoptosis**, and has antitumor activities.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## c-Met/HDAC-IN-2

Cat. No.: HY-143462

c-Met/HDAC-IN-2 is a highly potent **c-Met** and **HDAC** dual inhibitor with $IC_{50}$s of 18.49 nM and 5.40 nM for **HDAC1** and **c-Met**, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Cabozantinib

**(XL184; BMS-907351)**

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with $IC_{50}$s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



**Purity:** 99.96%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

## Cabozantinib-d4

**(XL184-d4; BMS-907351-d4)** Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with $IC_{50}$s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

## Capmatinib

**(INC280; INCB28060)** Cat. No.: HY-13404

Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive **c-Met** kinase inhibitor ($IC_{50}$=0.13 nM).



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

## CEP-40783

**(RXDX-106)** Cat. No.: HY-100946

CEP-40783 is a potent, selective and orally available inhibitor of **AXL** and **c-Met** with $IC_{50}$ values of 7 nM and 12 nM, respectively.



Purity: 99.22%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

## Crizotinib

**(PF-02341066)** Cat. No.: HY-50878

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with $IC_{50}$s of 20 and 8 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

## Crizotinib hydrochloride

**(PF-02341066 hydrochloride)** Cat. No.: HY-50878A

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual **ALK** and **c-Met** inhibitor with $IC_{50}$s of 20 and 8 nM, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

## Crizotinib-d5

**(PF-02341066-d5)** Cat. No.: HY-50878S

Crizotinib-d5 (PF-02341066-d5) is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with $IC_{50}$s of 20 and 8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## CSF1R-IN-2

Cat. No.: HY-111787

CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with $IC_{50}$ values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## DS-1205b free base

Cat. No.: HY-114357A

DS-1205b free base is a potent and selective inhibitor of **AXL kinase**, with an $IC_{50}$ of 1.3 nM. DS-1205b free base also inhibits **MER**, **MET**, and **TRKA**, with $IC_{50}$s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

## EGFR-IN-8

Cat. No.: HY-126320

EGFR-IN-8 is a dual **EGFR** and **c-Met** inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Ensartinib

**(X-396)** Cat. No.: HY-103714

Ensartinib (X-396) is a potent and dual **ALK/MET** inhibitor with **$IC_{50}$**s of <0.4 nM and 0.74 nM, respectively.



**Purity:** >98%
**Clinical Data:** Launched
**Size:** 1 mg, 5 mg

## Ensartinib dihydrochloride

**(X-396 dihydrochloride)** Cat. No.: HY-103714A

Ensartinib dihydrochloride (X-396 dihydrochloride) is a potent and dual **ALK/MET** inhibitor with **$IC_{50}$**s of <0.4 nM and 0.74 nM, respectively.



**Purity:** 99.46%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Foretinib

**(XL880; GSK1363089; GSK089; EXEL-2880)** Cat. No.: HY-10338

Foretinib is a multi-target tyrosine kinase inhibitor with **$IC_{50}$**s of 0.4 nM and 0.9 nM for **Met** and **KDR**.



**Purity:** 99.77%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Fosgonimeton

**(ATH-1017)** Cat. No.: HY-132814

Fosgonimeton (ATH-1017) is a **hepatocyte growth factor receptor** agonist (WO2017210489).



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Gemnelatinib

Cat. No.: HY-132816

Gemnelatinib is a **tyrosine kinase inhibitor** (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Glesatinib

**(MGCD265)** Cat. No.: HY-19642

Glesatinib (MGCD265) is an orally active, potent **MET/SMO** dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Glesatinib hydrochloride

**(MGCD265 hydrochloride)** Cat. No.: HY-19642A

Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent **MET/SMO** dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).



**Purity:** 98.25%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Glumetinib

**(SCC244)** Cat. No.: HY-116000

Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive **c-Met** inhibitor with an **$IC_{50}$** of 0.42 nM.



**Purity:** 98.15%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Golvatinib

**(E-7050)** Cat. No.: HY-13068

Golvatinib (E-7050) is a potent dual inhibitor of both **c-Met** and **VEGFR2** kinases with **$IC_{50}$**s of 14 and 16 nM, respectively.



**Purity:** 99.89%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## JNJ-38877605

Cat. No.: HY-50683

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.



**Purity:** 99.95%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## JNJ-38877618

Cat. No.: HY-111050

JNJ-38877618 is a potent, highly selective, orally bioavailable **Met** kinase inhibitor with $IC_{50}$s of 2 and 3 nM for wild type and mutant Met, respectively.



**Purity:** 98.26%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Meleagrin

Cat. No.: HY-N6797

Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of **FabI** inhibitor.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg

## Merestinib

**(LY2801653)**

Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable **c-Met** inhibitor ($K_i$=2 nM) with anti-tumor activities.



**Purity:** 99.99%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Merestinib dihydrochloride

**(LY2801653 dihydrochloride)**

Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable **c-Met** inhibitor ($K_i$=2 nM) with anti-tumor activities.



**Purity:** 99.36%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## MET kinase-IN-2

Cat. No.: HY-131065

MET kinase-IN-2 is a potent, selective, orally bioavailable **MET kinase** inhibitor with an $IC_{50}$ of 7.4 nM. MET kinase-IN-2 has antitumor activity.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## MGCD-265 analog

Cat. No.: HY-10991

MGCD-265 analog is a potent and oral active inhibitor of **c-Met** and **VEGFR2** tyrosine kinases, with $IC_{50}$s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.



**Purity:** 98.57%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

## MK-2461

Cat. No.: HY-50703

MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.



**Purity:** 99.87%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## MK-8033

Cat. No.: HY-13299

MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.



**Purity:** 95.02%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## MK-8033 hydrochloride

Cat. No.: HY-13299A

MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.



**Purity:** 99.70%
**Clinical Data:** Phase 1
**Size:** 5 mg, 10 mg, 50 mg

## Multi-kinase-IN-1

Cat. No.: HY-146014

Multi-kinase-IN-1 (Compound 11k) is a potent **kinase** inhibitor with antitumor activity.
Multi-kinase-IN-1 induces cell **apoptosis**, and can be studied for **colorectal cancer**.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Ningetinib

Cat. No.: HY-107145A

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with $IC_{50}$s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



**Purity:** 99.79%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Ningetinib Tosylate

Cat. No.: HY-107145

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with $IC_{50}$s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



**Purity:** 99.92%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Norleual

Cat. No.: HY-P1415

Norleual, an angiotensin (Ang) IV analog, is a **hepatocyte growth factor (HGF)/c-Met** inhibitor with an $IC_{50}$ of 3 pM. Norleual is an **AT4 receptor** antagonist and exhibits potent antiangiogenic activities.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## NPS-1034

Cat. No.: HY-100509

NPS-1034 is a dual inhibitor of **AXL** and **MET** with $IC_{50}$s of 10.3 and 48 nM, respectively.



**Purity:** ≥98.0%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## NVP-BVU972

Cat. No.: HY-15456

NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.



**Purity:** 98.38%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## Pamufetinib

**(TAS-115)**

Cat. No.: HY-12423

Pamufetinib (TAS-115) is a potent **VEGFR** and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor with $IC_{50}$s of 30 and 32 nM for rVEGFR2 and rMET, respectively.



**Purity:** >98%
**Clinical Data:** Phase 3
**Size:** 1 mg, 5 mg

## Pamufetinib mesylate

**(TAS-115 mesylate)**

Cat. No.: HY-12423A

Pamufetinib (TAS-115) mesylate is a potent **VEGFR**and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor, with $IC_{50}$s of 30 and 32 nM for rVEGFR2 and rMET, respectively.



**Purity:** 99.19%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## PF-04217903

Cat. No.: HY-12017

PF-04217903 is a potent ATP-competitive **c-Met kinase** inhibitor with $K_i$ of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.



**Purity:** 99.95%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## PF-04217903 methanesulfonate

Cat. No.: HY-12017A

PF-04217903 methanesulfonate is a potent ATP-competitive **c-Met kinase** inhibitor with $K_i$ of 4.8 nM for human c-Met. PF-04217903 methanesulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.



**Purity:** 99.87%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## PF-04217903 phenolsulfonate

Cat. No.: HY-12017B

PF-04217903 phenolsulfonate is a potent ATP-competitive **c-Met kinase** inhibitor with $K_i$ of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## PHA-665752

Cat. No.: HY-11107

PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of **c-Met** kinase ($K_i$=4 nM; $IC_{50}$=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

## S49076

Cat. No.: HY-12965

S49076 is a novel, potent inhibitor of **MET**, **AXL/MER**, and **FGFR1/2/3** with $IC_{50}$ values below 20 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

## SAR125844

Cat. No.: HY-16446

SAR125844 is a potent, highly selective, reversible and ATP-competitive **MET receptor tyrosine kinase (RTK)** inhibitor, with an $IC_{50}$ of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Savolitinib

**(Volitinib; HMPL-504; AZD-6094)**

Cat. No.: HY-15959

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable **c-Met** inhibitor with $IC_{50}$ s of 5 nM and 3 nM for c-Met and p-Met, respectively.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## SCR-1481B1

**(c-Met inhibitor 2)**

Cat. No.: HY-18711A

SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## SGX-523

Cat. No.: HY-12019

SGX523 is a exquisitely selective and ATP-competitive **MET** inhibitor. SGX523 potently inhibits MET with an $IC_{50}$ of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity.



Purity: 99.28%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

## SRI 31215 TFA

Cat. No.: HY-114363A

SRI 31215 (TFA), a triplex inhibitor of **matriptase**, **hepsin** and **hepatocyte growth factor activator (HGFA)** with $IC_{50}$s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## SU11274

**(PKI-SU11274)**

Cat. No.: HY-12014

SU11274 is a selective **Met** inhibitor with $IC_{50}$ of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## SYN1143

Cat. No.: HY-18307

SYN1143 is a potent, selective and orally active dual inhibitor of **c-Met/RON**, with $IC_{50}$s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on **Lck**, **Tie2**, **Src**, and **BTK** with $IC_{50}$s ranging from 160 to 710 nM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

## Terevalefim

**(ANG-3777)**

Cat. No.: HY-137455

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the **c-Met receptor**.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Tivantinib

**(ARQ 197)**

Cat. No.: HY-50686

Tivantinib is a highly selective **c-Met** tyrosine kinase inhibitor with a $K_i$ of 355 nM.



**Purity:** 99.67%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

## Tunlametinib

Cat. No.: HY-132844

Tunlametinib, an **antineoplastic** agent, is a **tyrosine kinase** inhibitor.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Tyrosine kinase inhibitor

Cat. No.: HY-10421

Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.



**Purity:** 99.96%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

## X-376

Cat. No.: HY-16590

X-376 is a potent and highly specific **ALK** tyrosine kinase inhibitor (TKI) ($IC_{50}$=0.61 nM). X-376 is a less potent inhibitor of **MET** ($IC_{50}$=0.69 nM). X-376 displays potent anti-tumor activity.



**Purity:** 98.36%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## XL092

Cat. No.: HY-138696

XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including **MET**, **VEGFR2**, **AXL** and **MER**, with $IC_{50}$s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity.



**Purity:** 99.52%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg